Migraine Research Studies

The THRIVE Trial is for people who experience migraines and whose usual medications to prevent migraines are not working well. A total of 150 participants between 18 and 75 years of age will take part in the trial.

The trial drug is approved in the USA and Europe for the preventive treatment of migraines in adults. This drug blocks a protein called calcitonin gene-related peptide (CGRP). It is believed that CGRP plays a role in migraines.

Drugs blocking CGRP or its receptor are approved and used for the preventive treatment of migraines. However, they do not always work well. There is no information about whether switching to another CGRP-targeting medication that works in a similar way might be effective. More research is needed to better understand how available medications work to prevent migraine attacks.

The trial will also continue to gather information on how safe the trial drug is, and what effect it may have on the participants’ ability to carry out daily activities.

You may be eligible to take part in the THRIVE Trial if you:

By joining the THRIVE Trial, you may receive:

For more information about the E-BEOND study, and to see if you may qualify,
please email ResearchNCNE@neurocenterne.com / call 781-551-5812 opt.6.

Step 1 of this study is currently open for enrollment. Step 1 is testing the safety of the investigational

drug, IPN10200. This will include checking whether IPN10200 has any side effects that might outweigh

its potential benefits.

The study will compare two different doses of IPN10200 with placebo. The study placebo looks exactly

like IPN10200, but does not contain any medically-active ingredients.

IPN10200 is based on botulinum toxins that doctors are able to give to people with migraine.

As a modified version, IPN10200 may have a longer-lasting effect than existing natural versions.

You may qualify if you: